17607 Gold Plaza, Omaha, NE
Patient Portal


The Real-Life Patient Impact of Pharmacy Benefit Managers

January 10, 2018

There is growing awareness of the problems and pitfalls with Pharmacy Benefit Managers (PBMs)
in the United States health care system. Contracted by insurance carriers to negotiate on their
behalf with pharmaceutical companies, these ‘middle men’ corporations have quietly become an
unavoidable part of our nation’s health care system.

Download Article

Apalutamide Granted FDA’s Priority Review for Nonmetastatic CRPC

December 26, 2017

Based on data from the phase III SPARTAN trial (ARN-509-003), apalutamide (ARN-509) has been granted a priority review by the FDA for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC), according to Janssen Biotech, the manufacturer of the next-generation oral androgen receptor inhibitor.

View Article

J&J announces positive data from the SPARTAN trial of apalutamide (ARN-509)

October 13, 2017

Janssen Biotech has submitted a New Drug Application to the US Food & Drug Administration for the approval of apalutamide (formerly ARN-509) in the treatment of non-metastatic, castration-resistant prostate cancer (nmCRPC).

View Article

First-Line Immunotherapy for Cisplatin-Ineligible Patients With Advanced Urothelial Cancer

October 13, 2017

first-line pembrolizumab (Keytruda) produced durable responses in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer in the phase II KEYNOTE-052 trial.

View Article

CMS’ 340B Reform Proposal Is a Good – Long Overdue – First Step

October 11, 2017

The 340B Drug Discount Program is an innocent-sounding program with the best of intentions. But behind it lies a classic tale of government run amok. After 25 years, this critically important safety net for patients in need has been overrun by some “corporate” hospitals that masquerade as nonprofits. While these bad actors make a killing off of 340B, the very patients it was intended to benefit suffer — and all of us taxpayers foot the bill.

View Article